Real‐World Experience of Efficacy and Tolerability of Continuous Infusion Ifosfamide for Advanced Soft Tissue and Bone Sarcoma Patients: A Single Centre Retrospective Cohort
ciIFO showed activity across different lines of therapy, achieving a DCR of 32%, and appeared better tolerated than standard-dose IFO regimens, even in a cohort of heavily pretreated patients (18% had an Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2). Synovial and bone sarcoma patients derived the greatest benefit (6-month PFS of 45% in both groups).
Authors
- Carlo Carnaghi (ORCID: https://orcid.org/0000-0002-8286-3728)
- Ferdinando Cananzi (ORCID: https://orcid.org/0000-0002-8227-3373)
- Erika Stucchi
- Alexia Bertuzzi (ORCID: https://orcid.org/0000-0002-8933-9929)
- Maria Susanna Grimaudo (ORCID: https://orcid.org/0009-0008-4530-0767)
- Marialudovica Le Moli
- Pierina Navarria
- Salvatore Lorenzo Renne (ORCID: https://orcid.org/0000-0002-0186-1318)
- Laura Giordano (ORCID: https://orcid.org/0000-0002-9587-7870)
- Elena Clerici (ORCID: https://orcid.org/0000-0002-1765-863X)
- Sara Farinatti
- Ilaria Mascagni (ORCID: https://orcid.org/0009-0008-3088-1255)
- Laura Samà
- Alice Laffi
- Robert G. Maki
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Humanitas University (IT)
- Cornell University (US)
- University of Catania (IT)
- Humanitas Gavazzeni (IT)
- IRCCS Humanitas Research Hospital (IT)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/cam4.71614
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministero della Salute
- Humanitas Research Hospital